HEMO Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. The company also treats for solid and rare cancers; and immune system and autoimmune diseases. Hemogenyx Pharmaceuticals Plc has entered in an agreement with Nitto Denko Corporation to evaluate targeted lipid nanoparticle delivery of Hemogenyx's CAR mRNA in vivo CAR-T therapy. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Hemogenyx Pharmaceuticals (LON: HEMO)
›
Hemogenyx Pharmaceuticals (LON: HEMO) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 16 employees.
The shares were at 690.50 GBp on 19 November 2026, down 19.3% over 52 weeks. Its 52-week range is 356.00 GBp to 1220.00 GBp: the price is 43.4% below the high and 94.0% above the low.
Its market capitalisation is 47.62M GBP.
Hemogenyx Pharmaceuticals reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 2.73M GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.